Capricor Therapeutics CAPR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's financing cash flow?
- Capricor Therapeutics (CAPR) reported financing cash flow of $1.47M in Q1 2026.
- How has Capricor Therapeutics's financing cash flow changed year-over-year?
- Capricor Therapeutics's financing cash flow increased by 2820.6% year-over-year, from $50.35K to $1.47M.
- What is the long-term trend for Capricor Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Capricor Therapeutics's financing cash flow has grown at a 87.3% compound annual growth rate (CAGR), from $20.23M to $248.89M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.